• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec23
Anthera Pharmaceuticals Completes Phase 3 Study for Non-Hormonal Menopause Drug
16:32
Dec17
Astellas and Pfizer Announce Positive Results from EV-304 Trial
11:47
Dec1
AstraZeneca Announces EMA Validates PADCEV Combination Therapy Application
01:42
Oct31
Astellas Pharma (ADR) Soars in Net Profit by 101% in First Half
00:17
Oct30
Astellas Pharma released FY2026 Q2 earnings on October 30 After-Market EST, actual revenue USD 3.528 B (forecast USD 3.232 B), actual EPS USD 0.2964
23:00
Astellas Pharma released FY2026 Semi-Annual Earnings on October 30 After-Market (EST), Actual Revenue: USD 7.023 B (Forecast: USD 6.36 B), Actual EPS: USD 0.5602
23:00

Schedules & Filings

Schedules
Filings
Oct30
Earning Release(EST)

FY2026 Q2 Earning Release (USD) Revenue 3.528 B, Net Income 532.95 M, EPS 0.2964

Sep30
Distribution Plan(EST)

Cash dividend 0.2698 USD

Distribution Plan(EST)

Cash dividend 0.2698 USD

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
PCLA
0.3600
+192.45%
+0.237
STEC
1.530
+59.38%
+0.570
HIHO
1.250
+50.60%
+0.420
TRIB
1.280
+43.50%
+0.388
EUDA
1.920
+41.18%
+0.560
AFJK
44.010
+37.49%
+12.000
SOC
10.360
+36.32%
+2.760
POM
0.3499
+30.95%
+0.083
ASTI
5.060
+30.41%
+1.180
ASPC
16.100
+29.42%
+3.660
View More